Brief: Palisade Bio Announces Completion Of Enrollment In LB1148 Dose Optimization Study
05/07/2023 13:51
July 5 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO ANNOUNCES COMPLETION OF ENROLLMENT IN LB1148
DOSE
OPTIMIZATION STUDY
* PALISADE BIO INC - TOPLINE DATA EXPECTED IN Q3 2023
Source text for Eikon: ID:nGNX6ZNLZJ
Further company coverage: PALI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing